The precision medicine market is projected to grow from USD 110.68 billion in 2025 to USD 237.28 billion by 2031, with a CAGR of 13.58%. Growth is driven by AI integration, biomarker advancements, next-gen sequencing (35%+ market share), and expanding adoption of targeted oncology therapies. North America leads the market, while Asia-Pacific emerges as a high-growth region.

Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share, payable on April 24, 2026 to shareholders of record on March 27, 2026.

Major M&A activity continues across multiple sectors: Starboard Value pushes TripAdvisor toward a sale, Hims & Hers acquires Eucalyptus for $1.15B to expand internationally, Danaher buys Masimo for $9.9B, Mister Car Wash goes private via Leonard Green for $3.1B, and Devon Energy completes a $21.4B merger with Coterra Energy. Meanwhile, Saks Global struggles with vendor shipments during bankruptcy, and Warner Bros. Discovery rejects Paramount's hostile bid.

Danaher agreed to acquire Masimo Corporation for $180 per share in an all-cash deal valued at $9.9 billion. The acquisition is expected to be accretive to earnings by $0.15-$0.20 in the first full year and approximately $0.70 by the fifth year, with projected annual synergies exceeding $175 million. Analysts view the deal as having sound financial rationale with strong recurring revenue and margin improvement potential.

Danaher Corp. is reportedly nearing a $9.9 billion acquisition of Masimo Corp., with an announcement potentially coming as early as Tuesday. The deal represents a significant premium to Masimo's $7 billion market cap and follows governance changes driven by activist investors. Masimo shares surged 34.51% on the news, while Danaher shares fell 5.22% in premarket trading.

A comprehensive market research report on over-the-counter and direct-to-consumer infectious disease diagnostics forecasts significant growth through 2029, driven by rapid testing technologies, privacy concerns, and digital accessibility. The report analyzes market trends across 15 countries, covering respiratory, STD, UTI, and other infectious disease testing channels, with profiles of 70+ diagnostic companies.

The global automated sample preparation market is expected to expand at a 10.10% CAGR from 2025 to 2031, driven by pharmaceutical R&D investments, need for reproducibility, and AI/ML adoption. However, high initial costs and integration challenges with legacy systems remain significant barriers, particularly for smaller laboratories and SMEs.

The global medical radiation detection devices market is projected to grow at ~7% CAGR through 2032, driven by rising cancer incidence, increased diagnostic imaging adoption, and stricter radiation safety regulations. North America leads the market, with Geiger-Müller counters as the largest product segment. Key players include Thermo Fisher Scientific, Ludlum Measurements, Mirion Technologies, and Canon Inc.

Danaher reported Q4 2025 sales of $6.84 billion, beating consensus estimates, with adjusted EPS of $2.23 exceeding expectations of $2.15. The company highlighted strength in bioprocessing and improved momentum in Diagnostics and Life Sciences. For fiscal 2026, Danaher expects core revenue growth of 3-6% and adjusted EPS of $8.35-$8.50, anticipating gradual improvement in end-market conditions. However, shares fell 2.23% following the announcement.

Jacobson & Schmitt Advisors increased its FirstService stake by 49,829 shares for $8.11 million in Q4, bringing total holdings to 144,994 shares (3.8% of portfolio). Despite shares lagging the S&P 500 by 25 percentage points over the past year, the fund sees value in FirstService's stable, recurring revenue model. Q3 results showed 4% revenue growth and 8% EPS growth, with solid fundamentals and low capital intensity supporting the investment thesis.

The global anatomic pathology market is projected to grow from $93.03 billion in 2024 to $224.44 billion by 2033 at a CAGR of 10.28%, driven by rising cancer burden, aging populations, and AI-powered digital pathology adoption. North America leads with over 41% market share, supported by advanced healthcare infrastructure and precision oncology investments. Disease diagnostics account for 74.42% of revenue, with cancer diagnostics representing 60% of biopsy applications globally.

The coding and marking solutions market is projected to grow from USD 8.62 billion in 2025 to USD 12.31 billion by 2031 at a 6.12% CAGR. Growth is driven by serialization requirements, traceability demands, and regulatory compliance. The industry is transitioning from solvent-based inks to fiber-laser systems, while cloud-hosted platforms and software services are reshaping the market. Asia-Pacific leads with 33.55% of global revenue, while semiconductor shortages continue to create cost pressures and sourcing challenges.